This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Sean Sheridan presents during the final session titled “Balancing Financial Risk in IP Licensing.”
For more information on this event, click here.
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...
Robert Goldman, Daniel McGavock, Dr. Richard Razgaitis, and Larry Rosenberg were recognized in the latest edition of IAM Strategy 300 – The World’s Leading IP...
CRA is a proud sponsor of this event. Larry Rosenberg conducts a roundtable discussion titled “Are licensing negotiation groups a suitable solution for SEP...
CRA is a proud sponsor of this event. Tim Simcoe moderates and Fei Deng speaks as a panelist during the session titled “What Next for New Madison? Current...
